个人中心 - 老虎社区

Msx01

IP属地：未知

帖子 · 149帖子 · 149
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- Msx01Msx01
  ·2021-11-15
  Pls like
  非常抱歉，此主贴已删除
  2,819 3
  7
  分享
  举报
- Msx01Msx01
  ·2021-11-13
  Pls like
  Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>
  Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo
  Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>
  2,683 1
  4
  分享
  举报
- Msx01Msx01
  ·2021-11-09
  $Marathon Digital Holdings Inc(MARA)$Happy [Grin]
  3,821 评论
  1
  分享
  举报
- Msx01Msx01
  ·2021-11-04
  Pls like
  5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023<blockquote>5只大盘股预计到2023年销售额将增长313%至1,304%</blockquote>
  These were some of the fastest-growing large-cap stocks on the planet over a three-year stretch.
  5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023<blockquote>5只大盘股预计到2023年销售额将增长313%至1,304%</blockquote>
  2,140 2
  4
  分享
  举报
- Msx01Msx01
  ·2021-11-04
  $AMC Entertainment(AMC)$Let’s go tonight!
  2,696 评论
  2
  分享
  举报
- Msx01Msx01
  ·2021-11-03
  $AMC Entertainment(AMC)$Yes yes haha
  2,018 评论
  点赞
  分享
  举报
- Msx01Msx01
  ·2021-11-03
  Blizzard What do you all think?
  2,236 评论
  点赞
  分享
  举报
- Msx01Msx01
  ·2021-11-02
  $AMC Entertainment(AMC)$Let’s go haha
  3,265 评论
  4
  分享
  举报
- Msx01Msx01
  ·2021-11-02
  Pls like
  非常抱歉，此主贴已删除
  2,640 1
  3
  分享
  举报
- Msx01Msx01
  ·2021-10-28
  Pls like
  非常抱歉，此主贴已删除
  3,752 1
  4
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3569922361666902","uuid":"3569922361666902","gmtCreate":1606828338564,"gmtModify":1627311458854,"name":"Msx01","pinyin":"msx01","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/c57e95b88f5085ec8c97e84ebccac4b9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":42,"headSize":222,"tweetSize":149,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.27%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":873229557,"gmtCreate":1636950003662,"gmtModify":1636950003854,"author":{"id":"3569922361666902","authorId":"3569922361666902","name":"Msx01","avatar":"https://static.tigerbbs.com/c57e95b88f5085ec8c97e84ebccac4b9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569922361666902","authorIdStr":"3569922361666902"},"themes":[],"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/873229557","repostId":"2183536049","repostType":4,"isVote":1,"tweetType":1,"viewCount":2819,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873904894,"gmtCreate":1636817319978,"gmtModify":1636817320206,"author":{"id":"3569922361666902","authorId":"3569922361666902","name":"Msx01","avatar":"https://static.tigerbbs.com/c57e95b88f5085ec8c97e84ebccac4b9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569922361666902","authorIdStr":"3569922361666902"},"themes":[],"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873904894","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示其研发实力雄厚。这对该股来说是一个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一早上，辉瑞公司首席科学官米凯尔·多尔斯滕(Mikael Dolsten)接到电话时，听起来很头晕。就在几天前，他的公司宣布其Covid-19抗病毒药物将高危成年人的住院风险降低了89%。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>多尔斯滕说：“你能够打破这种类型的世界纪录，同时偶然获得大满贯，这不可能只是一件随机的事情。”他在试图说明辉瑞的双重胜利：在短短10个月内开发出了一种效果惊人的Covid-19疫苗，一年后又开发出了一种同样令人惊叹的Covid-19抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉（Albert Bourla）要求投资者对多尔斯滕十多年来重建的研发业务进行豪赌。这个赌注看起来比以往任何时候都更聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla已经摆脱了辉瑞的非专利药物部门及其最后的消费者健康产品，留下了一家纯粹的生物制药公司，该公司的生死存亡都取决于Dolsten的科学实力。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在2019年11月的一篇封面报道中，<i>巴伦周刊</i>认为布尔拉和多尔斯滕可以成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞的理由<i>巴伦周刊</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从大流行中获利会带来新的风险。在全球超过70亿剂疫苗中，低收入国家仅占不到1%。如果辉瑞抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p><p><blockquote>数据公布当天，辉瑞股价飙升10.9%，创下至少20年来的最佳单日表现。尽管如此，由于该股目前易手价格约为50美元，投资者继续低估该公司的价值。投资者对辉瑞的定价是明年预期收益的12倍，低于强生(JNJ)和礼来(LLY)等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临专利悬崖的担忧。该公司将失去对少数年收入数十亿美元的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这些担忧是合理的，但辉瑞的科学政变应该让投资者相信该公司的科学能够安全地越过悬崖。市场可能需要时间才能赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞科学实力的最佳例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>虽然辉瑞的新冠肺炎疫苗来自德国生物技术公司BioNTech(BNTX)的实验室，但新的新冠肺炎抗病毒药物是由多尔斯滕所说的辉瑞位于美国东北部实验室的科学家“梦之队”研制出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将其工作分为与BioNTech在疫苗上的合作和对Covid-19药丸的探索。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的“巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目规模要小得多——一组辉瑞专家利用疫苗推广剩余的资源进行运营。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“小分子更像是一个灵活、专注于激光的高端团队，拥有相当适中的资源，”多尔斯滕说。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括药物设计主管夏洛特·阿勒顿。科学家们从辉瑞公司多年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p><p><blockquote>“（辉瑞的）制药研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂已经静脉内施用，并且当口服递送时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“他们必须真正创造很多新的化学反应，”多尔斯滕说。科学家们创造了600种化合物来确定正确的药物，这个过程通常可能需要数年时间，但他们在几个月内就完成了。“在这里，四年变成了四个月，”他说。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药物。该公司目前正在进行该药物的多项2/3期试验，包括一项针对高风险患者，一项针对非高风险患者，以及一项针对接触过病毒但尚未患病的患者的预防试验。在第一次读数中，该药物看起来比默克公司(MRK)的新冠治疗药物有效得多。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>Cantor Fitzgerald分析师Louise Chen表示：“这无疑有助于证明辉瑞的制药研发比人们想象的要好。”她对该股给予跑赢大盘评级，目标价为61美元。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈表示，在Covid-19疫苗和药丸销售的持久性更加明确以及其余产品得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“我认为没有一个事件会引发该股下一个级别的重新评级，”她说。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得对辉瑞的押注成为一项长期投资。与此同时，Moderna(MRNA)最近几周的经历凸显了疫苗制造商因疫苗分配不平等而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对Moderna越来越失望，呼吁该公司提高产量，以便能够以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司“挺身而出”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna股价在过去三个月下跌了40%以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞面临着侵蚀大约一年前推出Covid-19疫苗时赢得的巨大商誉的风险。本月早些时候，辉瑞首席执行官布尔拉指责低收入国家疫苗分配不公平，告诉<i>巴伦周刊</i>没有下订单是他们的错。辉瑞公司已以非营利价格向美国出售了10亿剂疫苗，捐赠给贫穷国家，并表示到明年年底将向中低收入国家提供总计至少20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>在抗病毒药物方面，辉瑞仅表示将为较贫穷国家提供分级定价，与其疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫穷国家提供自己的Covid-19药丸的计划形成鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，允许其药丸在全球范围内获得许可，无需向默克公司支付特许权使用费。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕表示，辉瑞正在考虑根据与默克类似的机制许可其药物。“我们将考虑这些选择，”他说。“我们绝不是说我们会做一些不同的事情。我们只是想确保参与其中的人都能获得这样做的建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的一步来得太快了。上月底，活动人士在布尔拉家外抗议，呼吁辉瑞分享其疫苗制造技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞公司相对受到华盛顿的青睐，并使其令人印象深刻的科学知识继续推动股价走高。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2683,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844315250,"gmtCreate":1636388313004,"gmtModify":1636388313668,"author":{"id":"3569922361666902","authorId":"3569922361666902","name":"Msx01","avatar":"https://static.tigerbbs.com/c57e95b88f5085ec8c97e84ebccac4b9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569922361666902","authorIdStr":"3569922361666902"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MARA\">$Marathon Digital Holdings Inc(MARA)$</a>Happy [Grin]&nbsp;","listText":"<a href=\"https://laohu8.com/S/MARA\">$Marathon Digital Holdings Inc(MARA)$</a>Happy [Grin]&nbsp;","text":"$Marathon Digital Holdings Inc(MARA)$Happy [Grin]","images":[{"img":"https://static.tigerbbs.com/9b39508f96e77ba601a462fa2cb5b5b0","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844315250","isVote":1,"tweetType":1,"viewCount":3821,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848478502,"gmtCreate":1636024656798,"gmtModify":1636024657534,"author":{"id":"3569922361666902","authorId":"3569922361666902","name":"Msx01","avatar":"https://static.tigerbbs.com/c57e95b88f5085ec8c97e84ebccac4b9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569922361666902","authorIdStr":"3569922361666902"},"themes":[],"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/848478502","repostId":"1144131531","repostType":4,"repost":{"id":"1144131531","kind":"news","pubTimestamp":1636022596,"share":"https://www.laohu8.com/m/news/1144131531?lang=zh_CN&edition=full","pubTime":"2021-11-04 18:43","market":"us","language":"en","title":"5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023<blockquote>5只大盘股预计到2023年销售额将增长313%至1,304%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1144131531","media":"Motley Fool","summary":"These were some of the fastest-growing large-cap stocks on the planet over a three-year stretch.","content":"<p><b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul>  <li>Be careful: Sales growth alone doesn't always give you the full story about a company.</li> </ul> Since the Great Recession ended in 2009, no group of companies has performed better than&nbsp;growth stocks. Historically low lending rates and the Federal Reserve's insistence on using quantitative-easing measures to keep rates low has led to abundant access to cheap capital.</p><p><blockquote><ul><li>小心：仅靠销售增长并不总是能让您了解一家公司的全部情况。</li></ul>自2009年大衰退结束以来，没有哪一组公司的表现比成长型股票更好。历史上较低的贷款利率和美联储坚持使用量化宽松措施来保持低利率，导致廉价资本的充足渠道。</blockquote></p><p> And it's not just small-cap stocks that are leaving a fiery trail of growth in their wake. According to consensus sales estimates from Wall Street, the following five&nbsp;large-cap stocks(companies with market caps of at least $10 billion) are all on pace to grow their annual sales by 313% to as much as 1,304% by 2023.</p><p><blockquote>不仅仅是小盘股留下了火热的增长轨迹。根据华尔街的一致销售额估计，以下五只大盘股（市值至少为100亿美元的公司）的年销售额都有望在2023年增长313%，达到1,304%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ddae655c5dfcf584e1db5b561b7b2051\" tg-width=\"2000\" tg-height=\"1529\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Nio: 447% implied sales growth by 2023</b></p><p><blockquote><b>蔚来：到2023年隐含销售额增长447%</b></blockquote></p><p> Electric-vehicle(EV) manufacturers should be some of the fastest-growing companies of the decade, and&nbsp;<b>Nio</b>(NYSE:NIO)&nbsp;is no exception. After the company produced $2.58 billion in sales last year, Wall Street's forecast calls for Nio to drive home roughly $14.1 billion in annual sales by 2023.</p><p><blockquote>电动汽车(EV)制造商应该是十年来增长最快的公司之一，并且<b>蔚来</b>（纽约证券交易所代码：蔚来）也不例外。继该公司去年实现25.8亿美元的销售额后，华尔街预测蔚来的评级到2023年将实现约141亿美元的年销售额。</blockquote></p><p> It's no secret that virtually all of the largest economies in the world are taking steps to fight climate change. Pushing consumers and enterprises to shift to EVs is one of the easiest ways to reduce carbon emissions. Nio is headquartered in the largest auto market in the world, China, which should see half of its annual vehicle sales be EVs or hybrids (mostly the former) by 2035, according to the Society of Automotive Engineers of China.</p><p><blockquote>众所周知，世界上几乎所有最大的经济体都在采取措施应对气候变化。推动消费者和企业转向电动汽车是减少碳排放最简单的方法之一。蔚来总部位于全球最大的汽车市场中国，根据中国汽车工程学会的数据，到2035年，中国汽车年销量的一半将是电动汽车或混合动力汽车（主要是前者）。</blockquote></p><p> Nio's rapid sales growth&nbsp;is being driven by its innovation. The company is introducing a new EV each year -- and its high-margin, loyalty-driven subscription program. Last year, it introduced a battery-as-a-service subscription program that'll allow buyers to upgrade or replace their batteries. This service also reduces the upfront cost of Nio's EVs.</p><p><blockquote>蔚来的快速销售增长是由其创新推动的。该公司每年都会推出一款新的电动汽车及其高利润、忠诚度驱动的订阅计划。去年，它推出了电池即服务订阅计划，允许买家升级或更换电池。这项服务还降低了蔚来电动汽车的前期成本。</blockquote></p><p> In exchange for giving up near-term sales, Nio is receiving high-margin monthly subscription revenue. More importantly, it's keeping buyers loyal to the brand.</p><p><blockquote>作为放弃近期销售的交换，蔚来正在获得高利润的月度订阅收入。更重要的是，它让买家对品牌保持忠诚。</blockquote></p><p> Assuming the auto industry can overcome recent chip shortages, Nio shouldn't have any trouble expanding its capacity and more than quintupling its sales in three years.</p><p><blockquote>假设汽车行业能够克服最近的芯片短缺问题，蔚来扩大产能并在三年内将销量增加五倍以上应该没有任何问题。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6a0952a9abfc3d69f1c7af0861a2d97b\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Snowflake: 401% implied sales growth by 2023</b></p><p><blockquote><b>Snowflake：到2023年隐含销售额增长401%</b></blockquote></p><p> Although double-digit sales growth is commonplace among cloud stocks, cloud data-warehousing company&nbsp;<b>Snowflake</b>(NYSE:SNOW)&nbsp;seems to be in a league of its own. In fiscal 2021, Snowflake brought in about $592 million in sales. By fiscal 2024, which ends in calendar year 2023, Wall Street is looking for Snowflake to generate almost $2.97 billion in revenue. That's a quintupling in sales, for those of you keeping score at home.</p><p><blockquote>尽管两位数的销售额增长在云股中司空见惯，但云数据仓储公司<b>雪花</b>（纽约证券交易所股票代码：SNOW）似乎独树一帜。2021财年，Snowflake的销售额约为5.92亿美元。到2023日历年结束的2024财年，华尔街预计Snowflake将产生近29.7亿美元的收入。对于那些在家记分的人来说，销售额增长了五倍。</blockquote></p><p> The Snowflake growth story&nbsp;is all about competitive advantages. For example, instead of opting for the popular subscription-based model, Snowflake charges its customers based on how much data they store and how many Snowflake Compute Credits used. This is a more transparent cost approach that its customers seem to like.</p><p><blockquote>雪花成长的故事是关于竞争优势的。例如，Snowflake没有选择流行的基于订阅的模式，而是根据客户存储的数据量和使用的Snowflake计算点数向客户收费。这是一种更透明的成本方法，其客户似乎很喜欢。</blockquote></p><p> Further, Snowflake's infrastructure is built atop the leading cloud-infrastructure service providers. This helps the company's clients work around data-sharing barriers that might otherwise exist between competing cloud platforms.</p><p><blockquote>此外，Snowflake的基础设施建立在领先的云基础设施服务提供商之上。这有助于该公司的客户解决竞争云平台之间可能存在的数据共享障碍。</blockquote></p><p> The big question is whether Snowflake can support its nosebleed valuation of 94 times projected fiscal 2022 sales, with profitability still a long way off. To that end, I'm not so sure -- but Ihave been proven wrong, thus far.</p><p><blockquote>最大的问题是，Snowflake能否支撑其2022财年预计销售额94倍的令人鼻血的估值，而盈利还有很长的路要走。为此，我不太确定——但到目前为止，我已经被证明是错的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/537b181fc66378021049916184ef4425\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Sea Limited: 322% implied sales growth by 2023</b></p><p><blockquote><b>Sea Limited：到2023年隐含销售额增长322%</b></blockquote></p><p> Another large-cap stock with big-time sales-growth expectations is Singapore-based&nbsp;<b>Sea Limited</b>(NYSE:SE). Sea reported $4.38 billion in sales last year. Come 2023, Wall Street is expecting roughly $18.5 billion in full-year revenue.</p><p><blockquote>另一只销售增长预期巨大的大盘股是新加坡<b>海有限公司</b>（纽约证券交易所代码：SE）。Sea去年的销售额为43.8亿美元。到2023年，华尔街预计全年收入约为185亿美元。</blockquote></p><p> Sea's not-so-secret key to success is its diversified trio of high-growth segments. First, there's digital entertainment, which is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea ended June with 725 million quarterly active mobile gamers, 12.7% of which were paying to play. This conversion rate&nbsp;is significantly higher than the industry average.</p><p><blockquote>Sea成功的关键不是什么秘密，而是其多元化的三个高增长细分市场。首先是数字娱乐，它是唯一一个产生正息税折旧摊销前利润(EBITDA)的行业。截至6月，Sea的季度活跃移动游戏玩家为7.25亿，其中12.7%是付费游戏。这一转化率明显高于行业平均水平。</blockquote></p><p></p><p> The company's&nbsp;most exciting segment&nbsp;is e-commerce platform Shopee, which has consistently been the most-downloaded shopping app in Southeastern Asia and has seen rapid growth in Brazil. To offer some context as to how quickly Shopee is growing, the gross merchandise value (GMV) transacted in the second quarter was $15 billion. Meanwhile, only $10 billion in GMV was registered on Shopee in all of 2018.</p><p><blockquote>该公司最令人兴奋的部分是电子商务平台Shopee，该平台一直是东南亚下载量最大的购物应用程序，并在巴西快速增长。为了提供有关Shopee增长速度的一些背景信息，第二季度的商品交易总额(GMV)为150亿美元。与此同时，2018年全年Shopee上注册的GMV仅为100亿美元。</blockquote></p><p> Lastly, Sea's nascent digital-wallet services segment is growing rapidly. The company is nearing 33 million paying mobile-wallet users. With Sea focusing on numerous underbanked regions, this digital financial-services segment could be a sneaky strong growth driver for years to come.</p><p><blockquote>最后，Sea新兴的数字钱包服务部门正在快速增长。该公司拥有近3300万付费移动钱包用户。随着Sea专注于众多银行服务不足的地区，这一数字金融服务领域可能会成为未来几年的强劲增长动力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2d05a27ae059e7e27dd31e695de449b2\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>AMC Entertainment: 313% implied sales growth by 2023</b></p><p><blockquote><b>AMC院线：到2023年隐含销售额增长313%</b></blockquote></p><p> Sometimes, sales growth alone doesn't give investors the full picture. For instance,movie-theater stock&nbsp;<b>AMC Entertainment</b>(NYSE:AMC)&nbsp;is slated to grow its sales from $1.24 billion in 2020 to an estimated $5.22 billion by 2023. However, the pandemic ravaged AMC and forced many of its theaters to temporarily close. This $5.22 billion estimate for 2023 still represents a decline from the $5.47 billion in sales recorded in 2019, the year prior to the pandemic.</p><p><blockquote>有时，仅靠销售增长并不能让投资者了解全貌。例如，电影院股票<b>AMC院线</b>（纽约证券交易所股票代码：AMC）的销售额预计将从2020年的12.4亿美元增长到2023年的52.2亿美元。然而，疫情肆虐AMC，迫使其许多影院暂时关闭。2023年52.2亿美元的销售额仍较大流行前一年2019年54.7亿美元的销售额有所下降。</blockquote></p><p> Whether it's industry or company specific,nothing seems to be working in AMC's favor. The movie-theater industry has been mired in a 19-year decline, with inflation-adjusted box-office gross sales falling 22% between 2002 and 2019.</p><p><blockquote>无论是行业还是公司具体情况，似乎都没有什么对AMC有利。电影业陷入了长达19年的下滑，2002年至2019年间，经通胀调整的票房总收入下降了22%。</blockquote></p><p> Even though AMC has been able to secure some exclusivity agreements with major studios, these agreements range from 30 to 45 days. Prior to the pandemic, theatrical exclusivity extended 75 to 90 days. There's no question that AMC has lost its bargaining power to studios, or that streaming is eating into its margins.</p><p><blockquote>尽管AMC已经能够与主要工作室达成一些独家协议，但这些协议的期限从30天到45天不等。在疫情之前，影院独占期延长了75至90天。毫无疑问，AMC已经失去了对工作室的议价能力，或者流媒体正在蚕食其利润。</blockquote></p><p> As for the company, it's unlikely to be profitable any time before 2024, and&nbsp;the math simply doesn't check out&nbsp;as to how it'll eventually pay back its $5.4 billion in outstanding debt, $420 million in deferred rent, and nearly $4.9 billion in long-term lease liabilities. With weekly box-office gross sales consistently down double digits from 2019, there's little doubt AMC will continue to burn through its remaining cash.</p><p><blockquote>至于该公司，在2024年之前的任何时候都不太可能盈利，而且数学根本无法确定它最终将如何偿还54亿美元的未偿债务、4.2亿美元的递延租金和近49亿美元的长期租赁负债。由于每周票房总额较2019年持续下降两位数，毫无疑问AMC将继续耗尽剩余现金。</blockquote></p><p> Even with \"rapid sales growth,\" some companies should be avoided like the plague.</p><p><blockquote>即使“销售快速增长”，也应该像躲避瘟疫一样避开一些公司。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b5fc13611f3bbe728494e0ef9d530643\" tg-width=\"2000\" tg-height=\"1334\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Moderna: 1,304% implied sales growth by 2023</b></p><p><blockquote><b>Moderna：到2023年隐含销售额增长1,304%</b></blockquote></p><p> The kingpin of sales growth on this list among large-cap companies is&nbsp;biotech-stock&nbsp;<b>Moderna</b>(NASDAQ:MRNA). In 2020, Moderna posted a little over $803 million in sales. By 2023, analysts expect this hot biotech stock to yield $11.28 billion in revenue. That's a better than 1,300% expected sales increase.</p><p><blockquote>这份大盘股公司中销售额增长的主力是生物科技股<b>现代</b>（纳斯达克：MRNA）。2020年，Moderna的销售额略高于8.03亿美元。到2023年，分析师预计这只热门生物科技股将产生112.8亿美元的收入。这比预期的1,300%的销售额增长要好。</blockquote></p><p> Chances are you're familiar with the Moderna name because of its success on the coronavirus disease 2019 (COVID-19) vaccine front. The company's vaccine, mRNA-1273, demonstrated 94% vaccine efficacy in a U.S. clinical trial released last November and has played a key role in inoculating adults in numerous developed markets.</p><p><blockquote>您可能对Moderna这个名字很熟悉，因为它在冠状病毒疾病2019（COVID-19）疫苗方面取得了成功。该公司的疫苗mRNA-1273在去年11月发布的美国临床试验中证明了94%的疫苗效力，并在众多发达市场的成人接种中发挥了关键作用。</blockquote></p><p> The&nbsp;big unknown for Moderna&nbsp;is what sort of legs mRNA-1273 will exhibit beyond 2021-2022. On one hand, variants of COVID-19 and the deterioration of vaccine efficacy over time suggests that booster shots may become a routine moving forward. This would offer Moderna a recurring revenue stream that it's never had before.</p><p><blockquote>Moderna最大的未知数是mRNA-1273在2021-2022年之后将展示什么样的腿。一方面，新冠肺炎的变种和疫苗效力随着时间的推移而恶化表明，加强注射可能会成为未来的常规。这将为Moderna提供前所未有的经常性收入来源。</blockquote></p><p> On the other hand, new vaccines are set to enter the space, and innovation could threaten Moderna's grip as a top-two COVID-19 player. For example, if competitors bring combination vaccines to market (e.g., COVID-19/influenza), it could make mRNA-1273 a less-tantalizing option.</p><p><blockquote>另一方面，新疫苗即将进入该领域，创新可能会威胁到Moderna作为COVID-19前两名参与者的地位。例如，如果竞争对手将联合疫苗推向市场（如新冠肺炎/流感），可能会使mRNA-1273成为一个不太诱人的选择。</blockquote></p><p> Considering that Moderna's $141 billion market cap is based on a single therapeutic, there's a lot of risk built into this stock.</p><p><blockquote>考虑到Moderna 1410亿美元的市值是基于单一治疗药物，该股票存在很大风险。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023<blockquote>5只大盘股预计到2023年销售额将增长313%至1,304%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023<blockquote>5只大盘股预计到2023年销售额将增长313%至1,304%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-11-04 18:43</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul>  <li>Be careful: Sales growth alone doesn't always give you the full story about a company.</li> </ul> Since the Great Recession ended in 2009, no group of companies has performed better than&nbsp;growth stocks. Historically low lending rates and the Federal Reserve's insistence on using quantitative-easing measures to keep rates low has led to abundant access to cheap capital.</p><p><blockquote><ul><li>小心：仅靠销售增长并不总是能让您了解一家公司的全部情况。</li></ul>自2009年大衰退结束以来，没有哪一组公司的表现比成长型股票更好。历史上较低的贷款利率和美联储坚持使用量化宽松措施来保持低利率，导致廉价资本的充足渠道。</blockquote></p><p> And it's not just small-cap stocks that are leaving a fiery trail of growth in their wake. According to consensus sales estimates from Wall Street, the following five&nbsp;large-cap stocks(companies with market caps of at least $10 billion) are all on pace to grow their annual sales by 313% to as much as 1,304% by 2023.</p><p><blockquote>不仅仅是小盘股留下了火热的增长轨迹。根据华尔街的一致销售额估计，以下五只大盘股（市值至少为100亿美元的公司）的年销售额都有望在2023年增长313%，达到1,304%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ddae655c5dfcf584e1db5b561b7b2051\" tg-width=\"2000\" tg-height=\"1529\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Nio: 447% implied sales growth by 2023</b></p><p><blockquote><b>蔚来：到2023年隐含销售额增长447%</b></blockquote></p><p> Electric-vehicle(EV) manufacturers should be some of the fastest-growing companies of the decade, and&nbsp;<b>Nio</b>(NYSE:NIO)&nbsp;is no exception. After the company produced $2.58 billion in sales last year, Wall Street's forecast calls for Nio to drive home roughly $14.1 billion in annual sales by 2023.</p><p><blockquote>电动汽车(EV)制造商应该是十年来增长最快的公司之一，并且<b>蔚来</b>（纽约证券交易所代码：蔚来）也不例外。继该公司去年实现25.8亿美元的销售额后，华尔街预测蔚来的评级到2023年将实现约141亿美元的年销售额。</blockquote></p><p> It's no secret that virtually all of the largest economies in the world are taking steps to fight climate change. Pushing consumers and enterprises to shift to EVs is one of the easiest ways to reduce carbon emissions. Nio is headquartered in the largest auto market in the world, China, which should see half of its annual vehicle sales be EVs or hybrids (mostly the former) by 2035, according to the Society of Automotive Engineers of China.</p><p><blockquote>众所周知，世界上几乎所有最大的经济体都在采取措施应对气候变化。推动消费者和企业转向电动汽车是减少碳排放最简单的方法之一。蔚来总部位于全球最大的汽车市场中国，根据中国汽车工程学会的数据，到2035年，中国汽车年销量的一半将是电动汽车或混合动力汽车（主要是前者）。</blockquote></p><p> Nio's rapid sales growth&nbsp;is being driven by its innovation. The company is introducing a new EV each year -- and its high-margin, loyalty-driven subscription program. Last year, it introduced a battery-as-a-service subscription program that'll allow buyers to upgrade or replace their batteries. This service also reduces the upfront cost of Nio's EVs.</p><p><blockquote>蔚来的快速销售增长是由其创新推动的。该公司每年都会推出一款新的电动汽车及其高利润、忠诚度驱动的订阅计划。去年，它推出了电池即服务订阅计划，允许买家升级或更换电池。这项服务还降低了蔚来电动汽车的前期成本。</blockquote></p><p> In exchange for giving up near-term sales, Nio is receiving high-margin monthly subscription revenue. More importantly, it's keeping buyers loyal to the brand.</p><p><blockquote>作为放弃近期销售的交换，蔚来正在获得高利润的月度订阅收入。更重要的是，它让买家对品牌保持忠诚。</blockquote></p><p> Assuming the auto industry can overcome recent chip shortages, Nio shouldn't have any trouble expanding its capacity and more than quintupling its sales in three years.</p><p><blockquote>假设汽车行业能够克服最近的芯片短缺问题，蔚来扩大产能并在三年内将销量增加五倍以上应该没有任何问题。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6a0952a9abfc3d69f1c7af0861a2d97b\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Snowflake: 401% implied sales growth by 2023</b></p><p><blockquote><b>Snowflake：到2023年隐含销售额增长401%</b></blockquote></p><p> Although double-digit sales growth is commonplace among cloud stocks, cloud data-warehousing company&nbsp;<b>Snowflake</b>(NYSE:SNOW)&nbsp;seems to be in a league of its own. In fiscal 2021, Snowflake brought in about $592 million in sales. By fiscal 2024, which ends in calendar year 2023, Wall Street is looking for Snowflake to generate almost $2.97 billion in revenue. That's a quintupling in sales, for those of you keeping score at home.</p><p><blockquote>尽管两位数的销售额增长在云股中司空见惯，但云数据仓储公司<b>雪花</b>（纽约证券交易所股票代码：SNOW）似乎独树一帜。2021财年，Snowflake的销售额约为5.92亿美元。到2023日历年结束的2024财年，华尔街预计Snowflake将产生近29.7亿美元的收入。对于那些在家记分的人来说，销售额增长了五倍。</blockquote></p><p> The Snowflake growth story&nbsp;is all about competitive advantages. For example, instead of opting for the popular subscription-based model, Snowflake charges its customers based on how much data they store and how many Snowflake Compute Credits used. This is a more transparent cost approach that its customers seem to like.</p><p><blockquote>雪花成长的故事是关于竞争优势的。例如，Snowflake没有选择流行的基于订阅的模式，而是根据客户存储的数据量和使用的Snowflake计算点数向客户收费。这是一种更透明的成本方法，其客户似乎很喜欢。</blockquote></p><p> Further, Snowflake's infrastructure is built atop the leading cloud-infrastructure service providers. This helps the company's clients work around data-sharing barriers that might otherwise exist between competing cloud platforms.</p><p><blockquote>此外，Snowflake的基础设施建立在领先的云基础设施服务提供商之上。这有助于该公司的客户解决竞争云平台之间可能存在的数据共享障碍。</blockquote></p><p> The big question is whether Snowflake can support its nosebleed valuation of 94 times projected fiscal 2022 sales, with profitability still a long way off. To that end, I'm not so sure -- but Ihave been proven wrong, thus far.</p><p><blockquote>最大的问题是，Snowflake能否支撑其2022财年预计销售额94倍的令人鼻血的估值，而盈利还有很长的路要走。为此，我不太确定——但到目前为止，我已经被证明是错的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/537b181fc66378021049916184ef4425\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Sea Limited: 322% implied sales growth by 2023</b></p><p><blockquote><b>Sea Limited：到2023年隐含销售额增长322%</b></blockquote></p><p> Another large-cap stock with big-time sales-growth expectations is Singapore-based&nbsp;<b>Sea Limited</b>(NYSE:SE). Sea reported $4.38 billion in sales last year. Come 2023, Wall Street is expecting roughly $18.5 billion in full-year revenue.</p><p><blockquote>另一只销售增长预期巨大的大盘股是新加坡<b>海有限公司</b>（纽约证券交易所代码：SE）。Sea去年的销售额为43.8亿美元。到2023年，华尔街预计全年收入约为185亿美元。</blockquote></p><p> Sea's not-so-secret key to success is its diversified trio of high-growth segments. First, there's digital entertainment, which is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea ended June with 725 million quarterly active mobile gamers, 12.7% of which were paying to play. This conversion rate&nbsp;is significantly higher than the industry average.</p><p><blockquote>Sea成功的关键不是什么秘密，而是其多元化的三个高增长细分市场。首先是数字娱乐，它是唯一一个产生正息税折旧摊销前利润(EBITDA)的行业。截至6月，Sea的季度活跃移动游戏玩家为7.25亿，其中12.7%是付费游戏。这一转化率明显高于行业平均水平。</blockquote></p><p></p><p> The company's&nbsp;most exciting segment&nbsp;is e-commerce platform Shopee, which has consistently been the most-downloaded shopping app in Southeastern Asia and has seen rapid growth in Brazil. To offer some context as to how quickly Shopee is growing, the gross merchandise value (GMV) transacted in the second quarter was $15 billion. Meanwhile, only $10 billion in GMV was registered on Shopee in all of 2018.</p><p><blockquote>该公司最令人兴奋的部分是电子商务平台Shopee，该平台一直是东南亚下载量最大的购物应用程序，并在巴西快速增长。为了提供有关Shopee增长速度的一些背景信息，第二季度的商品交易总额(GMV)为150亿美元。与此同时，2018年全年Shopee上注册的GMV仅为100亿美元。</blockquote></p><p> Lastly, Sea's nascent digital-wallet services segment is growing rapidly. The company is nearing 33 million paying mobile-wallet users. With Sea focusing on numerous underbanked regions, this digital financial-services segment could be a sneaky strong growth driver for years to come.</p><p><blockquote>最后，Sea新兴的数字钱包服务部门正在快速增长。该公司拥有近3300万付费移动钱包用户。随着Sea专注于众多银行服务不足的地区，这一数字金融服务领域可能会成为未来几年的强劲增长动力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2d05a27ae059e7e27dd31e695de449b2\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>AMC Entertainment: 313% implied sales growth by 2023</b></p><p><blockquote><b>AMC院线：到2023年隐含销售额增长313%</b></blockquote></p><p> Sometimes, sales growth alone doesn't give investors the full picture. For instance,movie-theater stock&nbsp;<b>AMC Entertainment</b>(NYSE:AMC)&nbsp;is slated to grow its sales from $1.24 billion in 2020 to an estimated $5.22 billion by 2023. However, the pandemic ravaged AMC and forced many of its theaters to temporarily close. This $5.22 billion estimate for 2023 still represents a decline from the $5.47 billion in sales recorded in 2019, the year prior to the pandemic.</p><p><blockquote>有时，仅靠销售增长并不能让投资者了解全貌。例如，电影院股票<b>AMC院线</b>（纽约证券交易所股票代码：AMC）的销售额预计将从2020年的12.4亿美元增长到2023年的52.2亿美元。然而，疫情肆虐AMC，迫使其许多影院暂时关闭。2023年52.2亿美元的销售额仍较大流行前一年2019年54.7亿美元的销售额有所下降。</blockquote></p><p> Whether it's industry or company specific,nothing seems to be working in AMC's favor. The movie-theater industry has been mired in a 19-year decline, with inflation-adjusted box-office gross sales falling 22% between 2002 and 2019.</p><p><blockquote>无论是行业还是公司具体情况，似乎都没有什么对AMC有利。电影业陷入了长达19年的下滑，2002年至2019年间，经通胀调整的票房总收入下降了22%。</blockquote></p><p> Even though AMC has been able to secure some exclusivity agreements with major studios, these agreements range from 30 to 45 days. Prior to the pandemic, theatrical exclusivity extended 75 to 90 days. There's no question that AMC has lost its bargaining power to studios, or that streaming is eating into its margins.</p><p><blockquote>尽管AMC已经能够与主要工作室达成一些独家协议，但这些协议的期限从30天到45天不等。在疫情之前，影院独占期延长了75至90天。毫无疑问，AMC已经失去了对工作室的议价能力，或者流媒体正在蚕食其利润。</blockquote></p><p> As for the company, it's unlikely to be profitable any time before 2024, and&nbsp;the math simply doesn't check out&nbsp;as to how it'll eventually pay back its $5.4 billion in outstanding debt, $420 million in deferred rent, and nearly $4.9 billion in long-term lease liabilities. With weekly box-office gross sales consistently down double digits from 2019, there's little doubt AMC will continue to burn through its remaining cash.</p><p><blockquote>至于该公司，在2024年之前的任何时候都不太可能盈利，而且数学根本无法确定它最终将如何偿还54亿美元的未偿债务、4.2亿美元的递延租金和近49亿美元的长期租赁负债。由于每周票房总额较2019年持续下降两位数，毫无疑问AMC将继续耗尽剩余现金。</blockquote></p><p> Even with \"rapid sales growth,\" some companies should be avoided like the plague.</p><p><blockquote>即使“销售快速增长”，也应该像躲避瘟疫一样避开一些公司。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b5fc13611f3bbe728494e0ef9d530643\" tg-width=\"2000\" tg-height=\"1334\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Moderna: 1,304% implied sales growth by 2023</b></p><p><blockquote><b>Moderna：到2023年隐含销售额增长1,304%</b></blockquote></p><p> The kingpin of sales growth on this list among large-cap companies is&nbsp;biotech-stock&nbsp;<b>Moderna</b>(NASDAQ:MRNA). In 2020, Moderna posted a little over $803 million in sales. By 2023, analysts expect this hot biotech stock to yield $11.28 billion in revenue. That's a better than 1,300% expected sales increase.</p><p><blockquote>这份大盘股公司中销售额增长的主力是生物科技股<b>现代</b>（纳斯达克：MRNA）。2020年，Moderna的销售额略高于8.03亿美元。到2023年，分析师预计这只热门生物科技股将产生112.8亿美元的收入。这比预期的1,300%的销售额增长要好。</blockquote></p><p> Chances are you're familiar with the Moderna name because of its success on the coronavirus disease 2019 (COVID-19) vaccine front. The company's vaccine, mRNA-1273, demonstrated 94% vaccine efficacy in a U.S. clinical trial released last November and has played a key role in inoculating adults in numerous developed markets.</p><p><blockquote>您可能对Moderna这个名字很熟悉，因为它在冠状病毒疾病2019（COVID-19）疫苗方面取得了成功。该公司的疫苗mRNA-1273在去年11月发布的美国临床试验中证明了94%的疫苗效力，并在众多发达市场的成人接种中发挥了关键作用。</blockquote></p><p> The&nbsp;big unknown for Moderna&nbsp;is what sort of legs mRNA-1273 will exhibit beyond 2021-2022. On one hand, variants of COVID-19 and the deterioration of vaccine efficacy over time suggests that booster shots may become a routine moving forward. This would offer Moderna a recurring revenue stream that it's never had before.</p><p><blockquote>Moderna最大的未知数是mRNA-1273在2021-2022年之后将展示什么样的腿。一方面，新冠肺炎的变种和疫苗效力随着时间的推移而恶化表明，加强注射可能会成为未来的常规。这将为Moderna提供前所未有的经常性收入来源。</blockquote></p><p> On the other hand, new vaccines are set to enter the space, and innovation could threaten Moderna's grip as a top-two COVID-19 player. For example, if competitors bring combination vaccines to market (e.g., COVID-19/influenza), it could make mRNA-1273 a less-tantalizing option.</p><p><blockquote>另一方面，新疫苗即将进入该领域，创新可能会威胁到Moderna作为COVID-19前两名参与者的地位。例如，如果竞争对手将联合疫苗推向市场（如新冠肺炎/流感），可能会使mRNA-1273成为一个不太诱人的选择。</blockquote></p><p> Considering that Moderna's $141 billion market cap is based on a single therapeutic, there's a lot of risk built into this stock.</p><p><blockquote>考虑到Moderna 1410亿美元的市值是基于单一治疗药物，该股票存在很大风险。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/11/04/5-large-cap-stocks-increase-sales-313-to-1304/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","NIO":"蔚来","SE":"Sea Ltd","MRNA":"Moderna, Inc.","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/11/04/5-large-cap-stocks-increase-sales-313-to-1304/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144131531","content_text":"Key Points\n\nBe careful: Sales growth alone doesn't always give you the full story about a company.\n\nSince the Great Recession ended in 2009, no group of companies has performed better than growth stocks. Historically low lending rates and the Federal Reserve's insistence on using quantitative-easing measures to keep rates low has led to abundant access to cheap capital.\nAnd it's not just small-cap stocks that are leaving a fiery trail of growth in their wake. According to consensus sales estimates from Wall Street, the following five large-cap stocks(companies with market caps of at least $10 billion) are all on pace to grow their annual sales by 313% to as much as 1,304% by 2023.\nIMAGE SOURCE: GETTY IMAGES.\nNio: 447% implied sales growth by 2023\nElectric-vehicle(EV) manufacturers should be some of the fastest-growing companies of the decade, and Nio(NYSE:NIO) is no exception. After the company produced $2.58 billion in sales last year, Wall Street's forecast calls for Nio to drive home roughly $14.1 billion in annual sales by 2023.\nIt's no secret that virtually all of the largest economies in the world are taking steps to fight climate change. Pushing consumers and enterprises to shift to EVs is one of the easiest ways to reduce carbon emissions. Nio is headquartered in the largest auto market in the world, China, which should see half of its annual vehicle sales be EVs or hybrids (mostly the former) by 2035, according to the Society of Automotive Engineers of China.\nNio's rapid sales growth is being driven by its innovation. The company is introducing a new EV each year -- and its high-margin, loyalty-driven subscription program. Last year, it introduced a battery-as-a-service subscription program that'll allow buyers to upgrade or replace their batteries. This service also reduces the upfront cost of Nio's EVs.\nIn exchange for giving up near-term sales, Nio is receiving high-margin monthly subscription revenue. More importantly, it's keeping buyers loyal to the brand.\nAssuming the auto industry can overcome recent chip shortages, Nio shouldn't have any trouble expanding its capacity and more than quintupling its sales in three years.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 401% implied sales growth by 2023\nAlthough double-digit sales growth is commonplace among cloud stocks, cloud data-warehousing company Snowflake(NYSE:SNOW) seems to be in a league of its own. In fiscal 2021, Snowflake brought in about $592 million in sales. By fiscal 2024, which ends in calendar year 2023, Wall Street is looking for Snowflake to generate almost $2.97 billion in revenue. That's a quintupling in sales, for those of you keeping score at home.\nThe Snowflake growth story is all about competitive advantages. For example, instead of opting for the popular subscription-based model, Snowflake charges its customers based on how much data they store and how many Snowflake Compute Credits used. This is a more transparent cost approach that its customers seem to like.\nFurther, Snowflake's infrastructure is built atop the leading cloud-infrastructure service providers. This helps the company's clients work around data-sharing barriers that might otherwise exist between competing cloud platforms.\nThe big question is whether Snowflake can support its nosebleed valuation of 94 times projected fiscal 2022 sales, with profitability still a long way off. To that end, I'm not so sure -- but Ihave been proven wrong, thus far.\nIMAGE SOURCE: GETTY IMAGES.\nSea Limited: 322% implied sales growth by 2023\nAnother large-cap stock with big-time sales-growth expectations is Singapore-based Sea Limited(NYSE:SE). Sea reported $4.38 billion in sales last year. Come 2023, Wall Street is expecting roughly $18.5 billion in full-year revenue.\nSea's not-so-secret key to success is its diversified trio of high-growth segments. First, there's digital entertainment, which is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea ended June with 725 million quarterly active mobile gamers, 12.7% of which were paying to play. This conversion rate is significantly higher than the industry average.\nThe company's most exciting segment is e-commerce platform Shopee, which has consistently been the most-downloaded shopping app in Southeastern Asia and has seen rapid growth in Brazil. To offer some context as to how quickly Shopee is growing, the gross merchandise value (GMV) transacted in the second quarter was $15 billion. Meanwhile, only $10 billion in GMV was registered on Shopee in all of 2018.\nLastly, Sea's nascent digital-wallet services segment is growing rapidly. The company is nearing 33 million paying mobile-wallet users. With Sea focusing on numerous underbanked regions, this digital financial-services segment could be a sneaky strong growth driver for years to come.\nIMAGE SOURCE: GETTY IMAGES.\nAMC Entertainment: 313% implied sales growth by 2023\nSometimes, sales growth alone doesn't give investors the full picture. For instance,movie-theater stock AMC Entertainment(NYSE:AMC) is slated to grow its sales from $1.24 billion in 2020 to an estimated $5.22 billion by 2023. However, the pandemic ravaged AMC and forced many of its theaters to temporarily close. This $5.22 billion estimate for 2023 still represents a decline from the $5.47 billion in sales recorded in 2019, the year prior to the pandemic.\nWhether it's industry or company specific,nothing seems to be working in AMC's favor. The movie-theater industry has been mired in a 19-year decline, with inflation-adjusted box-office gross sales falling 22% between 2002 and 2019.\nEven though AMC has been able to secure some exclusivity agreements with major studios, these agreements range from 30 to 45 days. Prior to the pandemic, theatrical exclusivity extended 75 to 90 days. There's no question that AMC has lost its bargaining power to studios, or that streaming is eating into its margins.\nAs for the company, it's unlikely to be profitable any time before 2024, and the math simply doesn't check out as to how it'll eventually pay back its $5.4 billion in outstanding debt, $420 million in deferred rent, and nearly $4.9 billion in long-term lease liabilities. With weekly box-office gross sales consistently down double digits from 2019, there's little doubt AMC will continue to burn through its remaining cash.\nEven with \"rapid sales growth,\" some companies should be avoided like the plague.\nIMAGE SOURCE: GETTY IMAGES.\nModerna: 1,304% implied sales growth by 2023\nThe kingpin of sales growth on this list among large-cap companies is biotech-stock Moderna(NASDAQ:MRNA). In 2020, Moderna posted a little over $803 million in sales. By 2023, analysts expect this hot biotech stock to yield $11.28 billion in revenue. That's a better than 1,300% expected sales increase.\nChances are you're familiar with the Moderna name because of its success on the coronavirus disease 2019 (COVID-19) vaccine front. The company's vaccine, mRNA-1273, demonstrated 94% vaccine efficacy in a U.S. clinical trial released last November and has played a key role in inoculating adults in numerous developed markets.\nThe big unknown for Moderna is what sort of legs mRNA-1273 will exhibit beyond 2021-2022. On one hand, variants of COVID-19 and the deterioration of vaccine efficacy over time suggests that booster shots may become a routine moving forward. This would offer Moderna a recurring revenue stream that it's never had before.\nOn the other hand, new vaccines are set to enter the space, and innovation could threaten Moderna's grip as a top-two COVID-19 player. For example, if competitors bring combination vaccines to market (e.g., COVID-19/influenza), it could make mRNA-1273 a less-tantalizing option.\nConsidering that Moderna's $141 billion market cap is based on a single therapeutic, there's a lot of risk built into this stock.","news_type":1,"symbols_score_info":{"MRNA":0.9,"SE":0.9,"SNOW":0.9,"NIO":0.9,"AMC":0.9}},"isVote":1,"tweetType":1,"viewCount":2140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848478301,"gmtCreate":1636024555896,"gmtModify":1636024556558,"author":{"id":"3569922361666902","authorId":"3569922361666902","name":"Msx01","avatar":"https://static.tigerbbs.com/c57e95b88f5085ec8c97e84ebccac4b9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569922361666902","authorIdStr":"3569922361666902"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Let’s go tonight!&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Let’s go tonight!&nbsp;","text":"$AMC Entertainment(AMC)$Let’s go tonight!","images":[{"img":"https://static.tigerbbs.com/31e80a25050fe6e6a7fdfefdf2d7a3ee","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848478301","isVote":1,"tweetType":1,"viewCount":2696,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841883685,"gmtCreate":1635901203908,"gmtModify":1635901204149,"author":{"id":"3569922361666902","authorId":"3569922361666902","name":"Msx01","avatar":"https://static.tigerbbs.com/c57e95b88f5085ec8c97e84ebccac4b9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569922361666902","authorIdStr":"3569922361666902"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Yes yes haha&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Yes yes haha&nbsp;","text":"$AMC Entertainment(AMC)$Yes yes haha","images":[{"img":"https://static.tigerbbs.com/0b7b82df624cac45dab64ff42e4bcb83","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841883685","isVote":1,"tweetType":1,"viewCount":2018,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841817607,"gmtCreate":1635901041351,"gmtModify":1635904192532,"author":{"id":"3569922361666902","authorId":"3569922361666902","name":"Msx01","avatar":"https://static.tigerbbs.com/c57e95b88f5085ec8c97e84ebccac4b9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569922361666902","authorIdStr":"3569922361666902"},"themes":[],"htmlText":"Blizzard&nbsp;What do you all think?&nbsp;","listText":"Blizzard&nbsp;What do you all think?&nbsp;","text":"Blizzard What do you all think?","images":[{"img":"https://static.tigerbbs.com/1a911bf041cdee5a6bc05279785a40fb","width":"1125","height":"3083"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841817607","isVote":1,"tweetType":1,"viewCount":2236,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841917997,"gmtCreate":1635868039924,"gmtModify":1635868040436,"author":{"id":"3569922361666902","authorId":"3569922361666902","name":"Msx01","avatar":"https://static.tigerbbs.com/c57e95b88f5085ec8c97e84ebccac4b9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569922361666902","authorIdStr":"3569922361666902"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Let’s go haha&nbsp;","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>Let’s go haha&nbsp;","text":"$AMC Entertainment(AMC)$Let’s go haha","images":[{"img":"https://static.tigerbbs.com/3e130a0a8c330ee51b718562c0322fa7","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841917997","isVote":1,"tweetType":1,"viewCount":3265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841915954,"gmtCreate":1635867922551,"gmtModify":1635867922759,"author":{"id":"3569922361666902","authorId":"3569922361666902","name":"Msx01","avatar":"https://static.tigerbbs.com/c57e95b88f5085ec8c97e84ebccac4b9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569922361666902","authorIdStr":"3569922361666902"},"themes":[],"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/841915954","repostId":"2180643782","repostType":4,"isVote":1,"tweetType":1,"viewCount":2640,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":855477014,"gmtCreate":1635396356951,"gmtModify":1635396357136,"author":{"id":"3569922361666902","authorId":"3569922361666902","name":"Msx01","avatar":"https://static.tigerbbs.com/c57e95b88f5085ec8c97e84ebccac4b9","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569922361666902","authorIdStr":"3569922361666902"},"themes":[],"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/855477014","repostId":"1120494800","repostType":4,"isVote":1,"tweetType":1,"viewCount":3752,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}